Dasatinib (original) (raw)

Nature Reviews Drug Discovery volume 5, pages 717–718 (2006)Cite this article

In June 2006, the tyrosine kinase inhibitor dasatinib (Sprycel; Bristol-Myers Squibb) was approved by the US FDA for the treatment of adults with chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia with resistance or intolerance to previous therapy, including the kinase inhibitor imatinib (Gleevec; Novartis).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1

References

  1. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330–1340 (1999).
    Article CAS Google Scholar
  2. Capdeville, R. et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493–502 (2002).
    Article CAS Google Scholar
  3. Shah, N. P. et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
    Article CAS Google Scholar
  4. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).
    Article CAS Google Scholar
  5. Lombardo, L. J. et al. Discovery of _N_-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661 (2004).
    Article CAS Google Scholar
  6. Tokarski, J. S. et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790–5797 (2006).
    Article CAS Google Scholar
  7. Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
    Article CAS Google Scholar
  8. FDA labelling information, [online] (2006).
  9. Ptasznik, A. et al. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR–ABL1(+) leukemia cells. Nature Med. 10, 1187–1189 (2004).
    Article CAS Google Scholar
  10. Donato, N. J. et al. BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690–698 (2003).
    Article CAS Google Scholar
  11. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR–ABL positive cells. Nature Med. 2, 561–566 (1996).
    Article CAS Google Scholar
  12. Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542–2551 (2006).
    Article Google Scholar

Download references

Author information

Authors and Affiliations

  1. the Leukemia Department, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, 77030, Texas, USA
    Hagop Kantarjian & Elias Jabbour
  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK
    Joanne Grimley
  3. Nature Reviews Drug Discovery,
    Peter Kirkpatrick

Authors

  1. Hagop Kantarjian
    You can also search for this author inPubMed Google Scholar
  2. Elias Jabbour
    You can also search for this author inPubMed Google Scholar
  3. Joanne Grimley
    You can also search for this author inPubMed Google Scholar
  4. Peter Kirkpatrick
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Kantarjian, H., Jabbour, E., Grimley, J. et al. Dasatinib.Nat Rev Drug Discov 5, 717–718 (2006). https://doi.org/10.1038/nrd2135

Download citation

This article is cited by